$110,000 of NOVOCURE INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025."
You can find more data on corporate lobbying on Quiver Quantitative.
NVCR Insider Trading Activity
NVCR insiders have traded $NVCR stock on the open market 16 times in the past 6 months. Of those trades, 4 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $NVCR stock by insiders over the last 6 months:
- ASHLEY CORDOVA (Chief Executive Officer) purchased 81,550 shares for an estimated $996,859
- FRANK X LEONARD (EVP, Pres., Novocure Oncology) has made 0 purchases and 3 sales selling 30,196 shares for an estimated $528,412.
- CHRISTOPH BRACKMANN (Chief Financial Officer) has made 3 purchases buying 20,000 shares for an estimated $231,800 and 0 sales.
- W ANTHONY VERNON sold 999 shares for an estimated $17,329
- TIMOTHY J SCANNELL sold 999 shares for an estimated $17,299
- GABRIEL LEUNG sold 999 shares for an estimated $17,297
- DAVID HUNG sold 999 shares for an estimated $17,279
- ALLYSON J OCEAN sold 999 shares for an estimated $17,269
- KRISTIN STAFFORD sold 999 shares for an estimated $17,258
- JERYL L HILLEMAN sold 999 shares for an estimated $17,246
- MARTIN J. MADDEN sold 999 shares for an estimated $17,175
- MUKUND PARAVASTHU (Chief Operating Officer) sold 592 shares for an estimated $10,604
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NVCR Hedge Fund Activity
We have seen 128 institutional investors add shares of NVCR stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 8,945,166 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $159,223,954
- SOLEUS CAPITAL MANAGEMENT, L.P. added 1,382,888 shares (+25.0%) to their portfolio in Q2 2025, for an estimated $24,615,406
- CAPITAL WORLD INVESTORS added 1,167,319 shares (+22.4%) to their portfolio in Q2 2025, for an estimated $20,778,278
- BLACKROCK, INC. added 1,086,692 shares (+8.3%) to their portfolio in Q2 2025, for an estimated $19,343,117
- AMERICAN CENTURY COMPANIES INC added 959,079 shares (+1354.7%) to their portfolio in Q2 2025, for an estimated $17,071,606
- DEERFIELD MANAGEMENT COMPANY, L.P. added 825,119 shares (+inf%) to their portfolio in Q2 2025, for an estimated $14,687,118
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 718,055 shares (+inf%) to their portfolio in Q2 2025, for an estimated $12,781,379
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NVCR Analyst Ratings
Wall Street analysts have issued reports on $NVCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 06/27/2025
To track analyst ratings and price targets for NVCR, check out Quiver Quantitative's $NVCR forecast page.
NVCR Price Targets
Multiple analysts have issued price targets for $NVCR recently. We have seen 3 analysts offer price targets for $NVCR in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Larry Biegelsen from Wells Fargo set a target price of $14.5 on 07/25/2025
- Kevin DeGeeter from Ladenburg Thalmann set a target price of $30.0 on 07/08/2025
- Jason Bednar from Piper Sandler set a target price of $34.0 on 06/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
